Cell Line Development and Characterization Services Markets Expected to Be Over $ 12 Billion by 2030, According to Roots Analysis

The growing preference for in vitro research models and expression systems has resulted in a strong demand for quality cell lines; during the pandemic, these cells expressing various antigens of SARS-CoV-2 helped to accelerate the development times of the therapy

/ EIN News / – London, July 14, 2021 (GLOBE NEWSWIRE) – Root analysis announced the addition of Cell Line Development and Characterization Services Market, 2020-2030 report to its list of offers.

The development and characterization of cell lines is both technically difficult and financially demanding; as a result, drug developers and academic institutions increasingly depend on contract service providers, who have the necessary infrastructure and adequate skills to perform advanced genetic engineering and routine analytical procedures in minimum time. with reduced risk of failure.

To order this 400+ page report, which contains over 150 figures and over 200 tables, please visit https://www.rootsanalysis.com/reports/cell-line-development-and-characterization-services.html

Key market information

Currently, more than 220 players claim to offer services for the development of cell lines
Almost 90% of the aforementioned players provide services for the development of mammalian cell lines, while more than half of the companies mentioned in the report (55%) have the expertise to develop microbial expression systems.

Over 80 companies currently offer different types of cell line characterization services

Almost 83% of the aforementioned players are able to assess the identity / stability of cell lines. Among the bioanalytical tests available, DNA fingerprinting / profiling is currently the most widely used technique in this field. For biosafety tests, the majority (37%) of companies state that they offer tests for the detection of mycoplasmas; of these, almost 25% also provide mycoplasma removal services.

There are more than 60 non-industrial players with cell line characterization capabilities

Almost 90% of these entities offer STR-based cell line authentication services, the majority (43%) of them using Promega’s GenePrint® 10 system to create human genetic profiles.

Partnership activity in this area increased at a CAGR of 18%, between 2015 and 2020
Over 330 partnership agreements were signed between industry players and sponsors during the given period; the majority of transactions were licensing agreements (23%), followed by mergers and acquisitions (18%). In 2020, nearly 30% of the agreements established focused on the R&D, manufacturing, licensing, marketing, distribution and supply of vaccines against the SARS-CoV-2 virus strain.

the cell line development services market expected to be worth more than $ 5.3 billion by 2030
Currently, the highest share of service revenues (82%) is estimated to come from development projects involving mammalian cell lines; this trend is also unlikely to change in the foreseeable future. In addition, the majority of market opportunities (80%) in 2030 are expected to come from GMP projects, focused on biotherapeutic production.

The cell line characterization services market is expected to grow at a CAGR of ~ 25% until 2030

In 2030, the highest market share (in terms of service revenues) is expected to be captured by North America (50%), followed by Europe (26%). It should be mentioned that service revenues in the Middle East, North Africa and Latin America are expected to grow at a relatively higher rate (CAGR> 15%) between 2020 and 2030.

To request a copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/cell-line-development-and-characterisation services / request-sample.html

Answers to key questions

  • Who are the main players offering cell line development services?
  • Who are the main industrial and non-industrial players offering cell line characterization services?
  • What are the most popular cell line development and characterization services compared to current demand?
  • What types of partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future opportunity likely to be distributed among key market segments?
  • What are the anticipated future trends related to cell line development and characterization services market?

The financial opportunity of 5.3 billion dollars (by 2030) in the cell line development services market was analyzed on the following segments:

  • Sources of proposed cell lines and expression systems
    • Applications of cell lines
    • size of the company
  • Key geographic regions
  • North America
  • Europe
  • Asia
  • Oceania
  • Rest of the world

The financial opportunity of $ 7.0 billion (by 2030) in the cell line characterization market was analyzed on the following segments:

    • Cell line sources available
    • Applications of cell lines
    • Type of service provider
  • Key geographic regions
  • North America
  • Europe
  • Asia
  • Latin America (LATAM)
  • Middle East and North Africa (MENA)
  • Rest of the world

The report presents contributions from prominent industry stakeholders that the competition in the cell line services market is expected to increase significantly resulting in a corresponding increase in the overall market value in the foreseeable future. The report includes detailed transcripts of the discussions (In reverse chronological order) outfit with the following people:

  • Jin Liang (President, Laragen)
  • Fai Poon (Founder and President, Quacell Biotechnology)
  • Louis Boon (Scientific Director, Polpharma Biologics)
  • Fan Chen (Former Vice President BioProcessing, LakePharma)
  • Michael Pointek (Founder and Managing Director, ARTES Biotechnology)
  • Nienke Smits (Head of Client Relations, Immunoprecise Antibodies)
  • Oscar Hoogteijling (Former Director of Global Business Development, Polpharma Biologics)

The report includes detailed profiles of the major players (listed below), each presenting an overview of the company, its financial information (if available), a description of the service (s) offered, details of recent developments related to development and characterization of cell lines offers, as well as an enlightened outlook for the future.

  • BioReliance
  • Charles River Laboratories
  • Creative biogen
  • Creative biolabs
  • Detai Bio-Tech
  • Eurofins BioPharma product tests
  • FUJIFILM Diosynth Biotechnologies
  • Hypercell
  • LacPharma
  • LivoGen Pharmed
  • Lonza
  • Molecular diagnostic services
  • ProBioGen
  • Polpharma Biologics
  • Sartorius Stedim Biotech
  • Selexis
  • GV
  • TFBS Biosciences
  • Thermo Fisher Scientific
  • WuXi organic products

For more details, please visit
or email [email protected]

You may also be interested in the following titles:

  1. Modular installations market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
  2. CAR-T Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
  3. Non-Viral Drug Delivery Systems Market: Industry Trends and Global Forecasts, 2021-2030
  4. Biopharmaceuticals contract manufacturing market (4th Edition): Industry Trends and Global Forecasts to 2030

Gaurav Chaudhary
                  [email protected]
                  Roots Analysis
                  A430, 4th Floor,
                  Bestech Business Towers, Sector 66, Mohali, India
                  [email protected]
                  +1 (415) 800 3415
                  +44 (122) 391 1091
                  Web: https://www.rootsanalysis.com/
                  LinkedIn: https://in.linkedin.com/company/roots-analysis
                  Twitter: https://twitter.com/RootsAnalysis

Main logo

Previous Clinical Trial Management Systems Market - Market players team up with virtual experts to capitalize on business opportunities
Next Manitoba Minister of Indigenous Relations Resigns Cabinet After Premier's Comments on Colonial History

No Comment

Leave a reply

Your email address will not be published.